Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Senores Pharmaceuticals Ltd. ( (IN:SENORES) ) is now available.
Senores Pharmaceuticals has reshaped its senior management structure by designating Chief Technology Officer Jatin Gajjar as Senior Management Personnel, effective March 17, 2026, following board approval based on the nomination and remuneration committee’s recommendation. Gajjar brings over 30 years of experience in pharmaceutical technology, complex formulations and process optimization, and will provide strategic leadership across R&D, manufacturing and regulatory affairs, reinforcing the company’s innovation-led growth agenda.
On the same date, President – Research and Development and Senior Management Personnel, Manohar Lalge, resigned with effect from the close of business hours, resulting in his cessation as part of the senior management team. The twin changes signal a consolidation of technology and R&D leadership under the CTO’s remit, potentially streamlining decision-making in product development and regulatory execution while marking a notable transition in the company’s R&D leadership bench.
More about Senores Pharmaceuticals Ltd.
Senores Pharmaceuticals Limited is an India-based drug maker headquartered in Ahmedabad, Gujarat, operating in the pharmaceutical industry with a focus on complex generics, injectable formulations and novel drug delivery technologies. The company emphasizes regulatory compliance, manufacturing efficiency and innovation across research and development, manufacturing and regulatory affairs to support commercialization in key markets.
Average Trading Volume: 23,671
Technical Sentiment Signal: Buy
Current Market Cap: 34.28B INR
For an in-depth examination of SENORES stock, go to TipRanks’ Overview page.